Latest news with #Esperion
Globe and Mail
07-08-2025
- Business
- Globe and Mail
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's vesting commencement date and will vest and become exercisable as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following such anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates. The RSUs are subject to the terms and conditions of Esperion's 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant. Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit and follow Esperion on LinkedIn and X.
Yahoo
22-07-2025
- Business
- Yahoo
Esperion to Report Second Quarter 2025 Financial Results on August 5
ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit and follow Esperion on LinkedIn and X. Esperion Contact Information: Investors: Alina Veneziainvestorrelations@ (734) 887-3903 Media: Tiffany Aldrich corporateteam@ (616) 443-8438Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
09-07-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report) and Esperion (ESPR – Research Report). Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. AbbVie (ABBV) In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on AbbVie. The company's shares closed last Tuesday at $189.77. According to Breen is a 2-star analyst with an average return of 3.3% and a 61.9% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company. AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $213.00, a 14.0% upside from current levels. In a report issued on July 1, Citi also maintained a Hold rating on the stock with a $205.00 price target. Esperion (ESPR) In a report released yesterday, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion, with a price target of $16.00. The company's shares closed last Tuesday at $1.17. According to Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.9% and a 29.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Adlai Nortye Ltd. Sponsored ADR, and Bioline RX Ltd Sponsored ADR. Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $6.37.
Globe and Mail
01-07-2025
- Business
- Globe and Mail
Esperion Appoints Craig Thompson to Board of Directors
ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson's appointment, Esperion's Board of Directors now comprises eight members. 'We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership and a proven track record advancing innovative therapies, Craig brings a wealth of strategic insight and operational expertise that will be invaluable as we continue to expand our impact in cardiovascular and cardiometabolic drug development. His deep understanding of pharmaceutical commercialization and clinical development aligns perfectly with our mission to deliver life-saving solutions to patients worldwide. We look forward to his contributions as we enter our next phase of growth and innovation,' stated Sheldon Koenig, President and CEO of Esperion. "I am honored to join the Board of Esperion, a company at the forefront of transforming cardiovascular disease prevention. With cardiovascular conditions remaining the leading cause of death globally, the need for innovative, proactive solutions has never been greater. I look forward to working alongside this exceptional team to help guide strategic decisions and accelerate the development of impactful, science-driven approaches that can improve and extend lives," said Mr. Thompson. Mr. Thompson has been the Chief Executive Officer and a member of the board of directors at Cerevance, a clinical stage biotechnology company focused on neurodegenerative, psychiatric, and CNS-controlled metabolic disorders, since April 2022. Mr. Thompson is also currently a member of the board of directors of NervGen Pharma Corp, a clinical stage biotechnology company focused on developing therapies for neurotrauma and neurologic diseases. Mr. Thompson was previously President & Chief Executive Officer and a member of the board of directors of Neurana Pharmaceuticals from June 2018 to April 2022. Prior to Neurana, Mr. Thompson was President & CEO of Anthera Pharmaceuticals Inc. Prior to Neurana, Mr. Thompson's biotechnology leadership experience included serving as Chief Operating Officer for Tetraphase Pharmaceuticals Inc. and as Chief Commercial Officer for Trius Therapeutics, Inc. where he was involved in the $700+ million acquisition of Trius Therapeutics by Cubist Pharmaceuticals, Inc., and led a partnership with Bayer Pharma AG. Before that, Mr. Thompson served in various global and U.S. leadership roles at Pfizer Inc., including Therapeutic Group Leader of Allergy, Respiratory, Pulmonary Vascular Disease and Inflammation; and he ultimately served as Vice President of Marketing for Pfizer's Specialty Care Business Unit. Previous to Pfizer, Mr. Thompson served in positions of increasing responsibility in global marketing at Merck & Co., where he was in product management for Zocor ®, including leading the rollout of the landmark Heart Protection Study. He also was instrumental in the pre-launch planning for Vytorin ® and Zetia ® as part of the European partnership between Merck and Schering-Plough. Mr. Thompson holds a Bachelor of Commerce degree from McMaster University and an MBA from the University of Notre Dame. About Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit and follow Esperion on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'predict,' 'project,' 'suggest,' 'target,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'continue,' and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion's commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.
Globe and Mail
12-06-2025
- Business
- Globe and Mail
Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts
Key Homozygous Familial Hypercholesterolemia Companies in the market include - Arrowhead Pharmaceutical, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Novartis, Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, Sanofi, Cerenis Therapeutics, Aegerion Pharmaceuticals, The Medicines Company, Akeso, Aegerion Pharmaceuticals, and others. DelveInsight's 'Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Homozygous Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Homozygous Familial Hypercholesterolemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Homozygous Familial Hypercholesterolemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Homozygous Familial Hypercholesterolemia Market Forecast Some of the key facts of the Homozygous Familial Hypercholesterolemia Market Report: The Homozygous Familial Hypercholesterolemia market size was valued approximately USD 108 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In March 2025, Esperion (NASDAQ: ESPR) has announced that, following discussions with the U.S. Food and Drug Administration (FDA), it has received regulatory alignment to proceed with Phase 3 clinical trials of bempedoic acid—both as a standalone therapy and in combination with ezetimibe—in pediatric patients with heterozygous and homozygous familial hypercholesterolemia (HeFH and HoFH). The company intends to launch these trials later this year. Notably, the FDA has previously granted orphan drug designation to bempedoic acid for the treatment of HoFH. In January 2025, LIB Therapeutics Inc. (LIB), a privately held, late-stage biopharmaceutical company developing Lerodalcibep—a next-generation PCSK9 inhibitor—announced that results from its Phase 3 LIBerate-HoFH trial have been published in The Lancet Diabetes & Endocrinology (Raal, F.J. et al., 2025). The study evaluated Lerodalcibep in a globally diverse population with homozygous familial hypercholesterolemia (HoFH). DelveInsight's 2022 analysis indicates that there were approximately 2,845 diagnosed prevalent cases of HoFH in the 7MM. This number is projected to rise significantly by 2034, with a notable CAGR throughout the study period (2020–2034). Estimates from DelveInsight's epidemiology model suggest that there were around 1,349 diagnosed prevalent cases of HoFH in the US in 2022. This number is projected to increase by 2034 over the study period (2020–2034). In the 7MM, the EU4 and the UK accounted for about 38% of the total diagnosed prevalent cases of HoFH in 2022, with expectations for this figure to rise further during the study period. According to DelveInsight's analysis, the United States alone represented approximately 47% of all diagnosed prevalent cases of HoFH among the 7MM in 2022. Key Homozygous Familial Hypercholesterolemia Companies: Arrowhead Pharmaceutical, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Novartis, Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, Sanofi, Cerenis Therapeutics, Aegerion Pharmaceuticals, The Medicines Company, Akeso, Aegerion Pharmaceuticals, and others Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, CER-001, lomitapide, ALN-PCSSC, AK102, AEGR-733, and others The Homozygous Familial Hypercholesterolemia epidemiology based on mutation-specific cases analyzed that a mutation in the LDLR gene accounted for the highest diagnosed prevalent cases in the US The Homozygous Familial Hypercholesterolemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Homozygous Familial Hypercholesterolemia pipeline products will significantly revolutionize the Homozygous Familial Hypercholesterolemia market dynamics. Homozygous Familial Hypercholesterolemia Overview Homozygous Familial Hypercholesterolemia (HoFH) is a rare and severe genetic disorder characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) from birth. It is caused by mutations in both alleles of genes involved in the clearance of LDL-C from the bloodstream, typically the LDL receptor gene. This condition leads to early and aggressive atherosclerosis, increasing the risk of heart attacks, strokes, and other cardiovascular diseases at a young age. Get a Free sample for the Homozygous Familial Hypercholesterolemia Market Forecast, Size & Share Analysis Report: Homozygous Familial Hypercholesterolemia Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Homozygous Familial Hypercholesterolemia Epidemiology Segmentation: The Homozygous Familial Hypercholesterolemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of HoFH in the 7MM Mutation-specific Diagnosed Prevalent Cases of HoFHin the 7MM Download the report to understand which factors are driving Homozygous Familial Hypercholesterolemia epidemiology trends @ Homozygous Familial Hypercholesterolemia Epidemiology Forecast Homozygous Familial Hypercholesterolemia Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Homozygous Familial Hypercholesterolemia market or expected to get launched during the study period. The analysis covers Homozygous Familial Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Homozygous Familial Hypercholesterolemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Homozygous Familial Hypercholesterolemia Therapies and Key Companies Homozygous Familial Hypercholesterolemia Market Strengths The clarity in disease understanding and pathogenesis has driven the development of novel pharmacological options like PCSK9 inhibitors, ANGPTL3 inhibitors, and MTP inhibitor Updated international diagnostic and clinical guidelines for FH and HoFH enable evidence-based therapeutic approaches and screening strategies for early identification Advances in research have led to the discovery of novel molecules like siRNA and recombinant fusion protein that may offer novel options to lower LDL significantly Homozygous Familial Hypercholesterolemia Market Opportunities Preclinical studies have yielded gene therapy and CRISPR-based gene editing approaches; conducting further research and clinical trials may offer curative therapy. Current therapies do not impart sufficient cholesterol-lowering allowing pharma players to bring newer, more potent, and better LDL-C lowering therapies and prevent ASCVD in HoFH patients. Advancements in healthcare technologies and digital health solutions can potentially enhance early detection and personalized management of HoFH. Scope of the Homozygous Familial Hypercholesterolemia Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Homozygous Familial Hypercholesterolemia Companies: Arrowhead Pharmaceutical, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Novartis, Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, Sanofi, Cerenis Therapeutics, Aegerion Pharmaceuticals, The Medicines Company, Akeso, Aegerion Pharmaceuticals, and others Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, CER-001, lomitapide, ALN-PCSSC, AK102, AEGR-733, and others Homozygous Familial Hypercholesterolemia Therapeutic Assessment: Homozygous Familial Hypercholesterolemia current marketed and Homozygous Familial Hypercholesterolemia emerging therapies Homozygous Familial Hypercholesterolemia Market Dynamics: Homozygous Familial Hypercholesterolemia market drivers and Homozygous Familial Hypercholesterolemia market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Homozygous Familial Hypercholesterolemia Unmet Needs, KOL's views, Analyst's views, Homozygous Familial Hypercholesterolemia Market Access and Reimbursement Table of Contents 1. Homozygous Familial Hypercholesterolemia Market Report Introduction 2. Executive Summary for Homozygous Familial Hypercholesterolemia 3. SWOT analysis of Homozygous Familial Hypercholesterolemia 4. Homozygous Familial Hypercholesterolemia Patient Share (%) Overview at a Glance 5. Homozygous Familial Hypercholesterolemia Market Overview at a Glance 6. Homozygous Familial Hypercholesterolemia Disease Background and Overview 7. Homozygous Familial Hypercholesterolemia Epidemiology and Patient Population 8. Country-Specific Patient Population of Homozygous Familial Hypercholesterolemia 9. Homozygous Familial Hypercholesterolemia Current Treatment and Medical Practices 10. Homozygous Familial Hypercholesterolemia Unmet Needs 11. Homozygous Familial Hypercholesterolemia Emerging Therapies 12. Homozygous Familial Hypercholesterolemia Market Outlook 13. Country-Wise Homozygous Familial Hypercholesterolemia Market Analysis (2020–2034) 14. Homozygous Familial Hypercholesterolemia Market Access and Reimbursement of Therapies 15. Homozygous Familial Hypercholesterolemia Market Drivers 16. Homozygous Familial Hypercholesterolemia Market Barriers 17. Homozygous Familial Hypercholesterolemia Appendix 18. Homozygous Familial Hypercholesterolemia Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
